BioSpace News Archive

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced that Dialco has engaged CROMSOURCE, a full-service Contract Research Organization (“CRO”), for its upcoming DIMI IDE usability clinical trial.

At Elekta’s (EKTA-B.ST) Capital Markets Day, CEO, Gustaf Salford , and members from his executive management team introduced the company’s mid-term strategy, called Access 2025. The strategy reflects the wor

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Natasha Drapeau, Executive Vice President of BioSig Technologies, Inc. would be presenting at the upcoming LD Micro Invitational XI event on Tuesday, June 8th, 2021, at 5 PM ET

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced positive proof-of-concept in vitro results and informative in vivo results with its new chemical entity (NCE), NVN4100, explored as a potential product candidate for topical antimicrobial indications in companion animal health.

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced that it is initiating a clinical trial at four burn centers in the United States.

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that 500 of its target 1,000 subjects have been enrolled in the Phase 3, RESUME-1 clinical study of tolperisone

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa , Chief Executive Officer of Relmada, is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 8:00 a.m. ET

BioCelerate, a subsidiary of TransCelerate BioPharma Inc. that focuses on identifying and developing pragmatic and tangible solutions to improve efficiencies in nonclinical research, today announced that it has released the first set of its solutions as part of its Public Private Partnership (PPP) with the U.S. Food & Drug Administration

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer® (“Reducer”) system has been granted national reimbursement in England as a result of being included in the High-Cost Tariff Excluded Devices (HCTED) national catalogue.

The SenSight™ Directional Lead System Was Designed to Enable Precision, Personalization and Enhanced Patient Comfort